To clarify the role of hepatitis G virus (HGV) infection in liver dysfunction following allogeneic BMT, we examined cryopreserved serum samples from 33 patients who had a history of blood transfusions before BMT and whose serum samples had been stored periodically, before BMT, on day 100, and thereafter for the presence of HGV-RNA and hepatitis C virus (HCV)-RNA by reverse transcription polymerase chain reaction. Nineteen patients (58%) out of 33 were positive for HGV-RNA before BMT and 10 for HCV-RNA. All patients positive for HCV-RNA were also positive for HGV-RNA. Patients were divided into three groups according to their viral status before BMT; namely, the G؉C؉ group (n = 10), the G؉C؊ group (n = 9) and the G؊C؊ group (n = 14). Two patients in the G؊C؊ group became positive for HGV-RNA after BMT. One patient in the G؉C؊ group suffered an acute exacerbation of hepatitis, with GPT levels reaching over 1000 IU/l, 2 and 3 years after BMT, showing quite a different clinical course from those in the G؉C؊ group. Excluding these three patients, GPT levels of the patients in the G؉C؉ group were significantly higher after day 100 and remained higher than those of patients in the G؉C؊ and G؊C؊ groups for at least 4 years. There were no significant differences in post-transplant GPT levels between the G؉C؊ group and the G؊C؊ group at any time point. Of the seven patients followed-up for 5 to 10 years, three patients became HGV-RNA-negative, while four remained positive. In the absence of HCV co-infection, the behavior of GPT values post transplant in patients with HGV infection did not differ from those without HGV infection. With respect to the patient who was G؉C؊ and showed high values of GPT 2 and 3 years post transplant, we suspect that his liver dysfunction might have been caused by some unknown virus or etiology. Keywords: GBV-C; HGV; BMT; liver function Correspondence: A Maruta, Department of Hematology/Chemotherapy, Kanagawa Cancer Center, 1-1-2 Nakao, Asahi-ku, Yokohama 241-0815, Japan Received 6 November 1998; accepted 15 March 1999
Two hepatitis-associated viruses, GB virus C (GBV-C) and hepatitis G virus (HGV), were identified in 1995 and in 1996.
1,2 These two viruses were found to show a 95% nucleotide homology, which was thought to indicate that they were isolates of the same virus, members of the Flaviviridae family. [1] [2] [3] The virus has been shown to be transmitted via parenterally administered blood or blood products. 4 In Japan the prevalence is estimated at 1.1% in voluntary donors without any markers of HCV or HBV infection. 5 There are many factors and pathologic conditions known to cause liver dysfunction after BMT, including drug-related toxicity, hepatic veno-occlusive disease (VOD), GVHD and viral hepatitis, due to infection with cytomegalovirus, herpes simplex virus, varicella zoster, adenovirus, hepatitis C virus (HCV) and hepatitis B virus (HBV). This retrospective study was performed to investigate the influence of HGV infection on the post-transplant clinical course and liver function, assessed on serum levels of glutamic pyruvic transaminase (GPT; alanine amino transferase, ALT), in BMT patients.
Materials and methods

Patients
We retrospectively studied 33 patients who had a history of receiving blood transfusions before BMT and whose serum samples had been stored periodically, before BMT, on day 100, and thereafter from among 105 patients who had received an allogeneic BMT between August 1987 and December 1996. We included one patient who had undergone a syngeneic BMT. One patient who was a carrier of hepatitis B was excluded. The clinical characteristics of patients are shown in Table 1 . The median follow-up period was 38 months (range, 15-127 months). There were 22 men and 11 women with a median age at BMT of 32 years (range, . Among the patients, 29 had acute leukemia, two myelodysplastic syndrome, and two severe aplastic anemia. Twenty-two patients received transplants from HLA-identical sibling donors, one from an identical twin, four alternative relatives, and six HLA-matched unrelated donors. Conditioning regimens in patients with acute leukemia or myelodysplastic syndrome were cytosine arabinoside (Ara-C), cyclophosphamide (CY), and fractionated 360  Table 1 Clinical features of patients according to pretransplant HGV and HCV positivity HGV = hepatitis G virus; HCV = hepatitis C virus; G(ϩ)C(Ϫ) = HGV-RNA positive and HCV-RNA negative; Ara-C = cytosine arabinoside; CY = cyclophosphamide; BU = busulfan; TBI = total body irradiation; TLI = total lymphoid irradiation; GVHD = graft-versus-host disease; a-= acute; c-= chronic; MTX = methotrexate; CsA = cyclosporin A.
total body irradiation (TBI) in 13, Ara-C, busulfan and CY in six, and thiotepa, CY and TBI in 13. Two patients with severe aplastic anemia were treated with CY and total lymphoid irradiation. Prophylaxis of acute GVHD consisted of short-term methotrexate and cyclosporin A in all patients but one identical twin recipient. GVHD was diagnosed based on clinical and histological findings and classified according to the established criteria. 6 VOD was diagnosed according to clinical findings. 7 
Detection of viral markers
With informed consent serum samples were obtained and stored at Ϫ80°C. Serum samples were collected just before conditioning, approximately on day 100 and 1-10 years post transplant. For the detection of HGV-RNA, reverse transcription polymerase chain reaction (RT-PCR) was performed as described by Chayama et al. 8 Briefly, RNA was extracted from 100 l of serum using SMITEST EX-R&D (Sumitomo Metal Industries, Tokyo, Japan) according to the manufacturer's specific instructions and was converted into cDNA using random hexamers and Moloney murine leukemia virus reverse transcriptase. cDNAs were amplified using a nested PCR with primers deduced from the 5Ј noncoding region of the GBV-C/HGV genome. The primers used were 5Ј-CACTATAGGTGGGTCTTAAG-3Ј (nt 150-169) and 5Ј-GCCTATTGGTCAAGAGAGAC-3Ј (nt 352-333) for the first PCR, and 5Ј-GCGCACGGTCCA-CAGGTGTT-3Ј (nt 207-226) and 5Ј-GGGCGACGTGGA-CCGTACGT-3Ј (nt 326-307) for the second PCR. Amplifications were performed for 30 cycles (94°C for 30 s, 53°C for 90 s, 72°C for 60 s) for the first PCR and for 35 cycles with the same time-temperature cycle for the second PCR. The PCR products were electrophoresed in 3% agarose gels, and bands were visualized by ethidium bromide staining.
Serum HCV-RNA was also determined by reverse transcription and nested PCR, using primers from the 5Ј-noncoding region of the HCV genome according to the method described by Okamoto et al. 9 The primers used were as follows: first cycle sense, 5Ј-CTGTGAGGAACT-ACTGTCTT-3Ј, antisense, 5Ј-ACCCAACACTACTCG-GCTAG-3Ј, second cycle sense 5Ј-TTCACGCAGAAA-GCGTCTAG-3Ј, and antisense, 5Ј-GTTGATCCAAGA-AAGGACCC-3Ј.
Statistical analysis
GPT values at each time point were compared using the Student's t-test.
Results
Prevalence of HGV and HCV infection
Nineteen (58%) out of 33 patients were found to be positive for HGV-RNA before BMT and 10 for HCV-RNA ( Figure  1) . None of the patients (0/14) who received blood transfusions after the introduction of donor screening by second- (Table 1) . Two patients became positive for HGV-RNA after BMT (Figure 1) .
Clinical course and analysis of liver function
One patient in the GϪCϪ group developed hepatic VOD. Grade уII acute GVHD was observed in two patients in the GϪCϪ group. Six patients in the GϩCϩ group, four in the GϩCϪ group and five patients in the GϪCϪ group developed extensive chronic GVHD. Post-transplant GPT levels of each patient are shown in Figure 2 . In the GϩCϪ group, one patient had an acute exacerbation of hepatitis with GPT levels over 1000 IU/l 2 and 3 years after BMT (Figure 2b ). In this patient the pattern of GPT levels was quite different from that of the other patients in the GϩCϪ group. So, excluding this patient and the two patients in the GϪCϪ group who became positive for HCV-RNA after BMT, liver function was evaluated in the three groups. Pretransplant GPT levels were 152 Ϯ 242 IU/l in the GϩCϩ group, 55 Ϯ 40 IU/l in the GϩCϪ group and 45 Ϯ 43 IU/l in the GϪCϪ group. However, no statistical differences were observed among them (GϩCϩ vs GϩCϪ, P = 0.28; GϩCϩ vs GϪCϪ, P = 0.15; GϩCϪ vs GϪCϪ, P = 0.61). GPT levels of the GϩCϩ group were significantly higher than those of the GϩCϪ group and the GϪCϪ group from day 100 to 1 year post transplant and decreased but remained at higher levels for several years. Two patients in the GϩCϩ group developed fulminant hepatitis and died on days 139 and 148, respectively, which has been described elsewhere. 10 There was no significant difference in post-transplant GPT levels between the GϩCϪ group and the GϪCϪ group at any time point.
With regard to alkaline phosphatase values (ALP), no significant difference was found throughout the post-transplant period among the three groups (data not shown).
Persistence of HGV-RNA
Three of the 19 patients positive for HGV-RNA before BMT became HGV-RNA-negative at 5 years or more post transplant. Of the seven patients followed-up for 5 years or more, three became HGV-RNA-negative, while four remained positive.
Discussion
We have documented a high prevalence of HGV infection (19/33, 58%) in bone marrow recipients who had received blood transfusions before BMT. This percentage is a little higher than those previously reported in the literature, 31% in Spain, 11 40% in France, 12 18% in Japan. 13 The incidence of HCV infection dramatically decreased to 0% from 53% after the introduction of screening using a second-generation ELISA for anti-HCV antibodies. Interestingly, HGV infection also decreased to 21% from 84%. However, the difference in the incidence of HGV infection could not be ascribed to the period when the patients were transfused, as we could not obtain precise data on the number of blood donors to whom each patient was exposed.
In the GϩCϪ group one patient showed episodes of acute exacerbation of liver function with GPT values reaching more than 1000 IU/l 2 and 3 years after BMT, which was quite a different course compared with that of the other patients in the group. We analyzed our data excluding this patient. The behavior of GPT levels in the GϩCϪ group after BMT was quite similar to that observed in the GϪCϪ group. GPT values of the GϩCϩ group were significantly higher than those of the GϩCϪ group and those of the GϪCϪ group at many time points after BMT, especially after day 100 when the immune system is reconstituting and the dose of cyclosporin A is reduced, as described elsewhere.
14 This suggests that HGV infection does not play any pathogenic role in liver function in patients who receive BMT, while HCV infection has a great influence on GPT levels at least for several years after BMT and may cause liver damage in long-term BMT survivors. These results were consistent with those of other reports. [11] [12] [13] 15 Two patients in the GϩCϩ group developed fulminant hepatitis and died on days 139 and 148. 10 We think it would be reasonable, from comparison between the GϩCϩ group and the GϩCϪ group, to say that the fulminant hepatitis in these two patients should be ascribed to HCV infection and not HGV infection, although there is a report which suggests that HGV can be responsible for fulminant hepatitis. 16 We excluded one patient from the final analysis of the data with HGV-RNA(ϩ)HCVϪRNA(Ϫ) who showed marked elevations of GPT levels during the clinical course after BMT. Based on our data, we consider that HGV had no influence on his liver dysfunction and suspect that liver dysfunction might have been caused by some unknown virus or etiology only because his clinical course was quite different from that of other HGV-RNA(ϩ)HCV-RNA(Ϫ) patients.
Some authors have suggested that patients with liver disease caused by HCV are at high risk of developing lethal hepatic VOD after BMT. 17 In our series, VOD occurred only in one HGV-RNA(Ϫ)HCV-RNA(Ϫ) patient. The presence of HGV infection or HCV infection before BMT was not a predictor of VOD in our studies, which was consistent with the results of other reports. 12, 13, 18 There has not been a report on the long-term follow-up of bone marrow recipients with HGV infection. None of the patients became HGV-RNA negative within 5 years in our study. HGV-RNA was, however, cleared in three of seven patients who have survived 5 years or more. The other four patients have remained positive for HGV-RNA for 5 to 9 years. Interestingly, HCV-RNA was also cleared in those three patients. HGV infection might be cleared with time as immunocompetence recovers.
In conclusion, in the absence of co-infection with HCV, the behavior of GPT levels after BMT in patients with HGV infection did not differ from those of patients without HGV infection. HGV infection before BMT has no impact on the outcome of BMT even in long-term survivors.
